# Marker Therapeutics, Inc.: funding, H-1B (November 2026)

Registers read on November 19, 2026.

Marker Therapeutics, Inc. (Texas) appears in 4 public registers SpecStream reads: 10 Form D filings, 2 certified H-1B and PERM cases, 5 SEC annual and quarterly reports and 4 NIH and NSF awards; the newest record is dated March 18, 2026, and the registers were read on November 19, 2026.

SpecStream is the live web data engine for teams and agents. This page joins the public registers SpecStream already reads for one company.

- Registers: 4
- Newest record: March 18, 2026
- State: Texas

## Form D filings (SEC)

10 Form D filings, newest December 30, 2024.

| Record | Date | Detail | Source |
| --- | --- | --- | --- |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | December 30, 2024 | $16.1 million sold of $16.1 million offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000110465924132525/0001104659-24-132525-index.htm) |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | May 24, 2018 | $3.1 million sold of $3.1 million offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000114420418030789/0001144204-18-030789-index.htm) |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | June 29, 2017 | $6.2 million sold of $6.2 million offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000109403817000002/0001094038-17-000002-index.htm) |
| [Form D amendment](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | September 9, 2016 | $3.1 million sold of $5 million offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000109403816000006/0001094038-16-000006-index.htm) |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | August 25, 2016 | $0 sold of an offering with no set size; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000109403816000005/0001094038-16-000005-index.htm) |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | August 23, 2016 | $2.4 million sold of $5 million offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000120919116138262/0001209191-16-138262-index.htm) |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | June 2, 2010 | $1.3 million sold of $1.3 million offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000142488410000069/0001424884-10-000069-index.htm) |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | November 10, 2009 | $700 thousand sold of $700 thousand offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000142488409000091/0001424884-09-000091-index.htm) |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | November 10, 2009 | $350 thousand sold of $350 thousand offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000142488409000090/0001424884-09-000090-index.htm) |
| [Form D](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038) | November 10, 2009 | $135 thousand sold of $135 thousand offered; Biotechnology | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000142488409000089/0001424884-09-000089-index.htm) |

- [Marker Therapeutics, Inc.](https://specstream.ai/data/form-d/company/marker-therapeutics-inc-1094038)
- [SEC EDGAR filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1094038&type=D)

## H-1B and PERM certifications (Department of Labor)

2 certified H-1B and PERM cases, newest June 8, 2023.

| Record | Date | Detail | Source |
| --- | --- | --- | --- |
| [Quality Control Microbiologist I](https://specstream.ai/data/hiring/employer/marker-therapeutics-inc-houston-tx) | June 8, 2023 | H-1B, 1 case, $62 thousand offered | [dol.gov](https://www.dol.gov/sites/dolgov/files/ETA/oflc/pdfs/LCA_Disclosure_Data_FY2023_Q3.xlsx) |
| [Quality Control Microbiologist III](https://specstream.ai/data/hiring/employer/marker-therapeutics-inc-houston-tx) | June 8, 2023 | H-1B, 1 case, $77.8 thousand offered | [dol.gov](https://www.dol.gov/sites/dolgov/files/ETA/oflc/pdfs/LCA_Disclosure_Data_FY2023_Q3.xlsx) |

- [Marker Therapeutics, Inc.](https://specstream.ai/data/hiring/employer/marker-therapeutics-inc-houston-tx)

## Public company financials (SEC)

5 SEC annual and quarterly reports, newest March 18, 2026.

- SEC central index key (CIK): 1094038
- Industry: SIC 2834, Pharmaceutical preparations
- Filer category: Non-accelerated filer

| Record | Date | Detail | Source |
| --- | --- | --- | --- |
| [10-K filed March 18, 2026](https://specstream.ai/data/public-companies/company/1094038-marker-therapeutics-inc) | March 18, 2026 | Revenue $3.5 million | [sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000110465926031274/0001104659-26-031274-index.htm) |

- [Marker Therapeutics, Inc.](https://specstream.ai/data/public-companies/company/1094038-marker-therapeutics-inc)

## NIH and NSF research awards

4 NIH and NSF awards, newest September 1, 2024.

| Record | Date | Detail | Source |
| --- | --- | --- | --- |
| [NIH](https://specstream.ai/data/research-funding/organization/marker-therapeutics-inc-ck3kr85csp23) | September 1, 2024 | A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic | [reporter.nih.gov](https://reporter.nih.gov/project-details/11180449) |
| [NIH](https://specstream.ai/data/research-funding/organization/marker-therapeutics-inc-ck3kr85csp23) | August 1, 2024 | A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed | [reporter.nih.gov](https://reporter.nih.gov/project-details/11164733) |
| [NIH](https://specstream.ai/data/research-funding/organization/marker-therapeutics-inc-ck3kr85csp23) | June 14, 2024 | Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy; $2 million | [reporter.nih.gov](https://reporter.nih.gov/project-details/11116994) |
| [NIH](https://specstream.ai/data/research-funding/organization/marker-therapeutics-inc-ck3kr85csp23) | August 10, 2023 | Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem | [reporter.nih.gov](https://reporter.nih.gov/project-details/11181329) |

- [Marker Therapeutics, Inc.](https://specstream.ai/data/research-funding/organization/marker-therapeutics-inc-ck3kr85csp23)

## How these records were matched

Records are joined when they carry the same SEC CIK, EIN or UEI, or when their legal names match word for word, legal form aside, at an address in the same state (Texas), and no register gives a second identifier, a second headquarters or a second filer of that name. Each record links to its own page and to the agency that published it.

Source: the registers named in each section. Public records of US federal and state agencies.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Texas

- [Pharmaceutical companies in Texas, United States](https://specstream.ai/data/businesses/pharmaceutical-companies/texas-united-states)
- [T-shirt printers in Texas, United States](https://specstream.ai/data/businesses/t-shirt-printers/texas-united-states)
- [Landscaping companies in Texas, United States](https://specstream.ai/data/businesses/landscaping-companies/texas-united-states)
- [Comfort food restaurants in Texas, United States](https://specstream.ai/data/businesses/comfort-food-restaurants/texas-united-states)
- [Taco restaurants in Texas, United States](https://specstream.ai/data/businesses/taco-restaurants/texas-united-states)
- [Language schools in Texas, United States](https://specstream.ai/data/businesses/language-schools/texas-united-states)
